The agreement grants Brinter the distribution rights of GrowInk bioinks in United States, Canada, Mexico, Finland, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Netherlands, Malta, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Australia and New Zealand.
Dr Johana Kuncova-Kallio, Director, UPM Biomedicals, said: “We are happy to enter into distribution agreement with Brinter, a Finnish-US company with global outreach. With Brinter, we are looking forward to entering even more company laboratories and hospitals with our GrowInk bioinks.”
Dr Eva Mueller, Head of Products, Brinter, added:: “This collaboration marks a significant milestone in advancing the field of 3D bioprinting and regenerative medicine together. We are excited about the impact this partnership will have on driving innovation in the life science and clinical sectors.”
UPM Biomedicals’ GrowInks are animal free, biocompatible,and ready-to-use hydrogels that can be mixed directly with cells for bioprinting applications.
The two main components in GrowInks are nanofibrillar cellulose and water, providing a fully defined matrix for living cells to grow in.
The bioinks can be customised by the addition of molecules, such as growth factors or adhesion proteins, or other biomaterials to customise the cell culture matrix for the specific needs of different cell types.
Ready-to-use and customisable GrowInks mimic the in vivo environment supporting cell growth and differentiation. More than 150 different cell types have been cultured in nanofibrillar cellulose.
They can easily be diluted to provide a wide range of stiffnesses that can be matched to the requirements of cells. GrowInks are room temperature stable, and they can be used with or without a crosslinking agent depending on the application.
GrowInks enable cell printing layer-by-layer with high-precision cell positioning.
